Enovis slightly beats Q2 sales estimates, reaffirms 2026 guidance
ENOV•Analyst view
The current average analyst rating on the shares is "buy", with 12 strong buy or buy ratings, 1 hold, and no sell or strong sell ratings.
The median 12-month price target is $40.00, about 32.5% above the stock's August 5 closing price of $30.18.
Q2 sales and EPS slightly beat estimates
Enovis said second-quarter sales rose 3%, slightly beating analyst expectations, while adjusted EPS also beat estimates.
The U.S. medical technology firm reported Q2 sales of $582.78 million, versus consensus of $582.54 million from 12 analysts. Adjusted EPS was $0.90, above the $0.85 estimate.
Q2 gross margin was 61.60%.
Reconstructive segment and execution drove results
Sales in the Reconstructive segment grew 8% on a reported basis and , reflecting continued execution and new product momentum.
